Inovio Pharmaceuticals Inc (NYSEMKT:INO) Acquires Global Rights For Therapies


Dallas, Texas 05/20/2014 (FINANCIALSTRENDS) –Inovio Pharmaceuticals Inc (NYSEMKT:INO) announced today it acquired global rights (with the exclusion of China) for its early pre-clinical therapies that address Alzheimer’s disease & multiple sclerosis that are based on academic research carried out by Dr. Bin Wang. He is a professor at the Furan University – Shanghai Medical College. Dr. Wang is the pioneer in this field of DNA-therapies, and has worked very closely with University of Pennsylvania’s Dr. David Weiner. Dr. Wang was the main author on certain of the earliest DNA-vaccine papers & patents.

The new technologies

With these rights in view, the company will now make the clinical and the regulatory milestone-payments to the University. The newly-licensed technologies are all based on the patent-protected and the published discoveries by Dr. Wang & his collaborator, who have found a very novel way of generating inducible-regulatory T cells/ iTreg. the iTreg cells are closely involved in shutting-down the immune responses after they successfully eliminate the invading organisms, & also in the prevention of autoimmunity or the inflammatory diseases. In the multiple published pre- clinical studies, this particular approach generated the CD25-iTreg in its antigen-specific manner.

The novel approach

The novel approaches could also be used to develop various therapies that target many major inflammatory diseases such as multiple sclerosis and might be used in the treatment of Alzheimer’s disease. Inovio Pharmaceuticals Inc (NYSEMKT:INO)’s chief executive officer, Dr. J. Joseph Kim said that acquiring the early-stage-technologies is just 1 more step in the company’s ultimate goal to control the immune system to fight various diseases in a much more safe & effective manner using the company’s immune engineering platform. INO’s therapeutic cancer-vaccines in this clinic are designed to also properly activate & direct the T cells to kill the cancer cells. The new candidates are also designed to do the exact opposite by shutting-down any unwanted & aberrant T cell responses.

Subscribe to get your free report!

* indicates required
*Past performance is not a predictor of future results. All investing involves risk of loss and individual investments may vary. The examples provided may not be representative of typical results. Your capital is at risk when you invest – you can lose some or all of your money. Never risk more than you can afford to lose.By submitting your information you agree to the terms of our Privacy Policy • Cancel Newsletter Any Time.This is a FREE service from Finacials Trend. Signing up for our FREE daily e-letter also entitles you to receive this report. We will NOT share your email address with anyone.